MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210 MorphoSys will receive a 15% equity stake in … [Read more…]